Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study
Open Access
- 21 January 2016
- journal article
- research article
- Published by Springer Nature in Infectious Diseases of Poverty
- Vol. 5 (1) , 1-6
Abstract
China’s national tuberculosis control program (NTP) provides free, first-line anti-tuberculosis (TB) drugs to pulmonary TB patients. This treatment regimen follows the World Health Organization’s (WHO) guideline. The objective of this paper is to evaluate the current status of anti-TB drug use for newly diagnosed pulmonary TB inpatients treated in prefecture- and county-level designated hospitals. Three prefecture-level hospitals and nine county-level hospitals were selected for the study. All newly diagnosed pulmonary TB inpatient medical records from 2012 were reviewed and doubly examined by two national senior physicians. The rational use of anti-TB drugs was evaluated based on criteria in line with WHO’s guideline. Of the 2,060 total treatment regimens for TB, 53.1 % were found to be rational (1093/2060). The percentages in prefecture-level and county-level hospitals were 50.3 % (761/1513) and 60.7 % (332/547), respectively. The difference between the two levels of hospitals was statistically significant (Chi-square value = 17.44, P < 0.01). The percentages of rational treatment regimens for first-time hospitalizations and for two or more hospitalizations were 59.5 % (983/1653) and 27.0 % (110/407), respectively, with a statistically significant difference (Chi-square value = 138.00, P < 0.01). The overall use of second-line drugs (SLD) was 54.9 % (1131/2060). The percentages for prefecture-level and county-level hospitals were 50.6 % (766/1513) and 66.7 % (365/547), respectively. A statistically significant difference was found (Chi-square value = 42.06, P < 0.01). The use of SLD for inpatients hospitalized once and inpatients hospitalized twice or more was 58.4 % (966/1653) and 40.5 % (165/407), respectively, with a statistically significant difference (Chi-square value = 42.26, P < 0.01). Half of inpatients might be treated with irrational regimens, and the use of SLD was more appropriately dispensed in city-level hospitals than in county-level hospitals. Trainings and guidelines for health personnel, supervision led by health authorities and increased investment to designated hospitals may help to improve the rational use of anti-TB drugs.Keywords
This publication has 19 references indexed in Scilit:
- Barriers to hospital and tuberculosis programme collaboration in China: context mattersGlobal Health Action, 2015
- Experiences in anti-tuberculosis treatment in patients with multiple previous treatments and its impact on drug resistant tuberculosis epidemicsGlobal Health Action, 2014
- China Tuberculosis Policy at Crucial Crossroads: Comparing the Practice of Different Hospital and Tuberculosis Control Collaboration Models Using Survey DataPLOS ONE, 2014
- Adverse drug reactions in the elderlyJournal of Pharmacology and Pharmacotherapeutics, 2013
- Comparing patient care seeking pathways in three models of hospital and TB programme collaboration in ChinaBMC Infectious Diseases, 2013
- Prevalence of inappropriate tuberculosis treatment regimens: a systematic reviewEuropean Respiratory Journal, 2011
- Tuberculosis patient expenditure on drugs and tests in subsidised, public services in China: a descriptive studyTropical Medicine & International Health, 2009
- Progress in tuberculosis control and the evolving public-health system in ChinaThe Lancet, 2007
- Barriers to effective tuberculosis control: a qualitative study.2005
- Retrospective descriptive study of adult tuberculosis in Wuhan, China.2004